IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be… More
In October the lead compound IMO2055 failed a phase II trial for renal cell carcinoma. What kept the stock from tanking more than 25% on the bad news, considering that the whole pipeline consists of related TLR9 agonists and antagonists? Probably the… More